Table 1 Clinical and metabolic features of the MMT-T1D Pilot Study population sample.
Variable | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 |
|---|---|---|---|---|---|---|---|---|---|---|
Sex | M | F | F | M | M | M | M | M | F | M |
Age (years) | 63 | 44 | 53 | 43 | 24 | 37 | 47 | 32 | 31 | 25 |
BMI (Kg·m−2) | 26.43 | 20.60 | 24.75 | 19.27 | 24.73 | 25.54 | 23.29 | 23.27 | 21.80 | 22.89 |
BSA (m2) | 1.91 | 1.47 | 1.63 | 1.72 | 1.80 | 1.97 | 1.99 | 1.89 | 1.73 | 1.83 |
HbA1c DCCT (%) | 8.0 | 8.3 | 7.1 | 7.2 | 7.8 | 8.7 | 8.6 | 7.3 | 7.8 | 7.2 |
HbA1c IFCC (mmol/mol) | 63.9 | 67.2 | 54.1 | 55.2 | 61.7 | 71.6 | 70.5 | 56.3 | 61.7 | 55.2 |
Duration of diabetes (years) | 9 | 18 | 12 | 34 | 8 | 24 | 40 | 19 | 22 | 13 |
Duration of CSII therapy (years) | 4 | 11 | 7 | 1 | 3 | 9 | 4 | 2 | 3 | 1 |
Insulin Sensitivity (M clamp) (μmol/min/m2 BSA) | 1655 | 649 | 1272 | 830 | 829 | 1152 | 719 | 825 | 1861 | 965 |
Insulin analogue | aspart | lispro | aspart | glulisine | aspart | aspart | glulisine | aspart | lispro | lispro |
MMT1 (292 Kcal) | • | • | • | • | • | • | • | • | • | • |
MMT2 (292 Kcal) | • | • | • | — | — | — | — | — | — | — |
MMT2 (600 Kcal) | — | — | — | • | • | • | — | — | — | — |
